PARIS--(BUSINESS WIRE)--Regulatory News:
Pixium Vision (FR0011950641 - PIX) (Paris:PIX), a company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, announced today that it will be delivering a presentation on one of its bionic vision products at the Jefferies Healthcare Conference in London on November 15-16, 2017. Khalid Ishaque, Chief Executive Officer, will be presenting as well as meeting with investors.
The presentation will be on November 16 at 8:00 AM GMT. Khalid Ishaque will discuss the latest updates on the development of PRIMA, Pixium Vision’s next generation miniaturized wireless sub-retinal photovoltaic implant. PRIMA is designed to treat vision loss from an advanced dry form of Age-Related Macular Degeneration (atrophic dry AMD) and also outer retinal dystrophies including Retinitis Pigmentosa (RP). Pixium Vision recently received approval from the French regulatory authority, Agence Nationale de Sécurité du Médicament et des Produits de santé (ANSM), for PRIMA to start a feasibility clinical trial in France to evaluate the device. The clinical trial will be initially evaluating PRIMA’s treatment for the atrophic dry form of AMD. In parallel, Pixium Vision actively pursues its constructive discussions with the US Food and Drug Administration (FDA), in order to also prepare the feasibility study with PRIMA in the US.
The presentation will be webcast live. To access the webcast please visit www.pixium-vision.com or connect directly to http://wsw.com/webcast/jeff108/pix.pa/ . The webcast will remain available for 90 days following the presentation.
ABOUT PIXIUM VISION
Pixium Vision’s mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy and quality of life. Pixium Vision’s bionic vision systems are associated with a surgical intervention as well as a rehabilitation period. Following the CE mark for its epi-retinal Bionic Vision System, IRIS®II, Pixium Vision has been authorized to start clinical study in Human for PRIMA, a sub-retinal miniaturized wireless implant system. No human clinical data on PRIMA is yet available. Pixium Vision collaborates closely with academic and research partners spanning across the prestigious Vision research institutions including the Institut de la Vision in Paris, the Hansen Experimental Physics Laboratory at Stanford University, and Moorfields Eye Hospital in London. The company is EN ISO 13485 certified.
Pixium Vision is qualified “Entreprise Innovante” par Bpifrance
Pixium Vision is listed on Euronext Paris (Compartment C). Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.
Pixium Vision is included in the Euronext CAC All Shares index
Euronext ticker: PIX - ISIN: FR0011950641 – Reuters: PIX.PA – Bloomberg: PIX:FP
This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.
Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.
For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company’s Registration Document filed with the AMF under number R16-033 on April 28, 2016 which can be found on the websites of the AMF - AMF (www.amf-france.org) and of Pixium Vision (www.pixium-vision.com).
IRIS® is a trademark of Pixium-Vision SA